Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07315854) titled 'Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy in the Treatment of Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer' on Dec. 20, 2025.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Beijing Friendship Hospital
Condition:
Gastric Cancer (GC)
Gastroesophageal Junction Cancer
Advanced Gastric Cancer
Metastatic Gastric Cancer
Intervention:
Drug: Iparomlimab and Tuvonralimab (QL1706)
Recruitment Status: Re...